

Patients, analysed	297 (100.0)
Age (years)	8.5 (4.0-12.2)
< 6 years	112 (37.7)
6-10 years	66 (22.2)
> 10 years	119 (40.1)
at diagnosis of β -TM	0.8 (0.4-1.2)
at start of transfusion therapy	0.7 (0.5-1.2)
at start of chelation therapy	2.8 (2.0-4.5)
Gender	297 (100.0)
Female	145 (48.8)
Male	152 (51.2)
Origin	297 (100.0)
Europe	131 (44.1)
North Africa	154 (51.9)
Rest of Africa	1 (0.3)
North America	6 (2.0)
Latin America	1 (0.3)
Asia	4 (1.4)
β-TM type	84 (100.0)
β^0 / β^0	23 (27.4)
β^0 / β^+	28 (33.3)
β^+ / β^+	30 (35.7)
Hb Lepore / β^0	1 (1.2)
Hb Lepore / β^+	1 (1.2)
$\delta\beta / \beta^+$	1 (1.2)
Transfusional iron intake (mg/kg/day)	293 (100.0)
Low (< 0.3)	46 (15.7)
Intermediate (0.3-0.5)	197 (67.2)
High (> 0.5)	50 (17.1)
Annual blood requirement (mL pure RBC/kg/year)	125 (117-156)
Spleen status	289 (100.0)
Normal	51 (17.7)
Splenomegaly	168 (58.1)
Splenectomised	70 (24.2)
Serum ferritin (ng/mL)	268 (100.0)
< 2,000 ng/mL (n, %)	143 (53.4)
2,000-4,000 ng/mL (n, %)	93 (34.7)
> 4,000 ng/mL (n, %)	32 (11.9)
HIV seropositive (n = 183)	0 (0.0)
Hepatitis B seropositive (n = 237)	10 (4.2)
Hepatitis C seropositive (n = 242)	41 (16.9)
Values are median (IQR) and number of patients n (%), if not stated otherwise.	

Table 5. DEEP-3 patient demographics and baseline characteristics